Friday, 23 Mar 2018

You are here

RheumNow Week in Review - 29 July 2016

Dr Jack Cush reviews this week's highlights from

  1. RA: risk of serious infection rises with Interstitial lung dz; 2 fold higher in 1st yr; higher with BOOP & steroids >10mg/day.
  2. FDA warns against using fluoroquinolones (to Rx UTI, bronchitis etc) if other safer Rx options exist.
  3. Quercetin shown to signif. reduce Uric acid, it inhibits xanthine oxidoreductase in vitro. Not studied in gout.
  4. CHMP has recommended abatacept for 1st line use (before MTX) in moderate to severe RA. EMA to consider approval
  5. Anakinra not effective if added to MTX in early RA: CARDERA2 study of 154pts Rx x2yrs. No xray benefit, less DAS/HAQ
  6. UK audit of 5000 RA shows only 20% referred from GP to Rheum in 3days (NICE target). Wait time to see Rheum 23-34d
  7. FDA Panel Recommends Brodalumab Approval in Psoriasis
  8. Pravastatin Improves Obstetric Outcomes in Anti-Phospholipid Syndrome Patients. 
  9. Long-Term Safety of Adalimumab Reviewed
  10. MACRA for the Overwhelmed Rheumatologist
  11. The Purse Exam: a Forgotten Part of the Physical. 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.